The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://alyshaehfn355847.webdesign96.com/39120433/retatrutide-vs-tirzepatide-a-comparative-analysis